(NASDAQ: IMTX) Immatics Nv's forecast annual revenue growth rate of -10.8% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 85.29%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.87%.
Immatics Nv's revenue in 2025 is $151,313,953.On average, 1 Wall Street analysts forecast IMTX's revenue for 2025 to be $6,334,465,910, with the lowest IMTX revenue forecast at $6,334,465,910, and the highest IMTX revenue forecast at $6,334,465,910. On average, 2 Wall Street analysts forecast IMTX's revenue for 2026 to be $7,655,817,751, with the lowest IMTX revenue forecast at $7,146,483,417, and the highest IMTX revenue forecast at $8,165,152,085.
In 2027, IMTX is forecast to generate $14,410,879,555 in revenue, with the lowest revenue forecast at $14,410,879,555 and the highest revenue forecast at $14,410,879,555.